To investigate the effectiveness and safety of the homeopathic product SilAtro-5-90 in recurrent tonsillitis. In this international, pragmatic, controlled clinical trial, 256 patients (6-60 years) with moderate recurrent tonsillitis were randomized to receive either SilAtro-5-90 in addition to standard symptomatic treatment, or to receive standard treatment only. The primary outcome was the mean time period between consecutive acute throat infections (ATI) within 1 year (analyzed via repeated events analysis). During the evaluation year, the risk of getting an ATI was significantly lower (hazard ratio: 0.45, proportional means model, p = 0.0002, ITT) with SilAtro-5-90 compared to control. Tonsillitis-specific symptoms were significantly reduced (p < 0.0001, ITT) and the need of antibiotics to treat acute throat infections (p = 0.0008; ITT) decreased. 3 non-serious adverse drug reactions were reported for SilAtro-5-90. An integrative treatment approach where SilAtro-5-90 is given alongside mainstream symptomatic treatment may bring therapeutic benefit to patients suffering from recurrent tonsillitis. ISRCTN registry: Registration number ISRCTN19016626, registered 23 January 2013.
Experimental work carried out over the past 20 years to study the activity of various functional groups in tonsillar cells in patients with chronic tonsillitis (CT) under local exposure to various immune response modifiers showed that: - tonsillar cells from CT patients in 69.5% of cases are capable of increasing their immunofunctional activity under the influence of immune modifiers in vitro reactions; - the most active of the group of immunotropic immune response modifiers are T-activin and Thymogen; - it can be considered the optimal diagnostic technique to carry out a "stress" test on the tonsil tissue using nonspecific (alternating magnetic field of industrial (low) frequency and low-frequency ultrasound) and specific — a microbial vaccine when applied to the tonsil tissue; - a non-invasive method for recording changes in the tonsils after stimulation may be fluctuations in the level of secretory immunoglobulin A and α-interferon in saliva after the test; - an increase in the level of secretory immunoglobulin A and α-interferon by more than 1/3 of the initial level after the test is a clinically favorable sign and a recommendation for medical treatment to the managing of patients with CT.